Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
3-(5-{[4-(aminomethyl)piperidin-1-yl]methyl}-1H-indol-2-yl)quinolin-2(1H)-one
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
This compound is a synthetic small molecule with the chemical formula C24H26N4O and a molecular weight of approximately 386.49 g/mol. It is classified as an experimental drug and has not been approved for clinical use or assigned any therapeutic indication. The primary known mechanism of action is inhibition of serine/threonine-protein kinase Chk1 (Checkpoint kinase 1), with reported in vitro activity (IC50 ~140 nM). Chk1 inhibitors are being explored as potential anticancer agents due to their role in cell cycle regulation and DNA damage response, but there are no records of this specific compound entering clinical trials or being developed by a pharmaceutical company for any disease area[2][7].
- Other names
- 3-(5-{[4-(Aminomethyl)piperidin-1-Yl]methyl}-1h-Indol-2-Yl)quinolin-2(1h)-One3-(5-{[4-(aminomethyl)piperidin–1–yl]methyl}–1H–indol–2–yl)quinolin–2(1H)–one3-(5-{[4-(aminomethyl)piperidin‑1‑yl]methyl}‑1H‑indol‑2‑yl)quinolin‑2(1H)‑one
02
Targets
CHEK1 (Checkpoint kinase 1)
Beyond the preview
Go deeper on 3-(5-{[4-(aminomethyl)piperidin-1-yl]methyl}-1H-indol-2-yl)quinolin-2(1H)-one.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 3-(5-{[4-(aminomethyl)piperidin-1-yl]methyl}-1H-indol-2-yl)quinolin-2(1H)-one.